Upadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trial.

Bennett, Michaela; Sinclair, Rodney D; Eisman, Samantha

Bennett, Michaela; Sinclair, Rodney D; Eisman, Samantha.

Bennett M; Sinclair Dermatology, Melbourne, Victoria, Australia.
Sinclair RD; Sinclair Dermatology, Melbourne, Victoria, Australia.
Eisman S; University of Melbourne, Melbourne, Victoria, Australia.

Australas J Dermatol ; 64(1): 146-150, 2023 Feb.

Article in English | MEDLINE | ID: covidwho-2251847

ABSTRACT

ABSTRACT

Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)-1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single-centre Australian cohort.

Subject(s)

Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; Janus Kinase Inhibitors; Humans; Australia; Dermatitis, Atopic/drug therapy; Retrospective Studies; Janus Kinase Inhibitors/therapeutic use; Treatment Outcome

Keywords

JAK 1 inhibitors; JAK inhibitor treatment; Upadacitinib; atopic dermatitis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis, Atopic / Drug-Related Side Effects and Adverse Reactions / Janus Kinase Inhibitors Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Country/Region as subject: Oceania Language: English Journal: Australas J Dermatol Year: 2023 Document Type: Article Affiliation country: Ajd.13969

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google